{"nctId":"NCT03748823","briefTitle":"Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","startDateStruct":{"date":"2019-02-19","type":"ACTUAL"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria"],"count":139,"armGroups":[{"label":"Ravulizumab SC Treatment Group","type":"EXPERIMENTAL","interventionNames":["Combination Product: Ravulizumab OBDS","Biological: Ravulizumab"]},{"label":"Ravulizumab IV Treatment Group","type":"ACTIVE_COMPARATOR","interventionNames":["Combination Product: Ravulizumab OBDS","Biological: Ravulizumab"]}],"interventions":[{"name":"Ravulizumab OBDS","otherNames":[]},{"name":"Ravulizumab","otherNames":["ALXN1210"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ≥18 years of age\n* Treated with eculizumab for PNH for at least 3 months prior to Day 1\n* LDH level ≤1.5 × upper limit of normal (ULN) at screening\n* PNH diagnosis confirmed by documented high-sensitivity flow cytometry.\n* Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.\n* Body weight ≥40 to \\<100 kilogram (kg)\n* Female participants of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab.\n* Willing and able to give written informed consent and comply with study visit schedule.\n\nExclusion Criteria:\n\n* More than 1 LDH value \\> 2 × ULN within the 3 months prior to study entry\n* History of bone marrow transplantation.\n* History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the Investigator or Sponsor, would preclude participation.\n* Unstable medical conditions (for example, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within 6 months of randomization, coexisting chronic anemia unrelated to PNH).\n* Females who are pregnant, breastfeeding or who have a positive pregnancy test at screening or Day 1.\n* Participation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that investigational product, whichever is greater.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ctrough Serum Concentration of Ravulizumab","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"457.58","spread":"108.491"},{"groupId":"OG001","value":"578.70","spread":"140.819"}]}]}]},{"type":"SECONDARY","title":"Ctrough Serum Concentration of Ravulizumab at Day 351","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"712.79","spread":"203.180"},{"groupId":"OG001","value":"737.65","spread":"208.894"}]}]}]},{"type":"SECONDARY","title":"Free Serum Complement Component 5 (C5) Concentrations at Day 71","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.072193","spread":"0.0245225"},{"groupId":"OG001","value":"0.059458","spread":"0.0182180"}]}]}]},{"type":"SECONDARY","title":"Free Serum Complement Component 5 (C5) Concentrations at Day 351","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.071627","spread":"0.0227980"},{"groupId":"OG001","value":"0.069711","spread":"0.0208784"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lactate Dehydrogenase (LDH) Levels at Day 71","description":"Baseline was defined as the last assessment prior to first study drug dose. LDH samples impacted by tabletop hemolysis were excluded from the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.73","spread":"29.716"},{"groupId":"OG001","value":"2.57","spread":"33.883"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDH Levels at Day 351","description":"SC baseline was defined as the last assessment prior to first dose of SC treatment. LDH samples impacted by tabletop hemolysis were excluded from the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"17.225"},{"groupId":"OG001","value":"1.74","spread":"21.905"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Subscale Version 4 Score at Day 71","description":"FACIT-fatigue subscale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Items are scored on a 5 point Likert-type scale. Item scores ranged from 0 (\"not at all\") to 4 (\"very much\"). The total, summed score ranged from 0 to 52; lower scores indicating greater fatigue and higher score indicating better health-related quality of life. Baseline was defined as the last non-missing value prior to the first dose of study drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"7.378"},{"groupId":"OG001","value":"1.21","spread":"7.882"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FACIT-Fatigue Scale Version 4 Score at Day 351","description":"FACIT-fatigue subscale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Items are scored on a 5 point Likert-type scale. Item scores ranged from 0 (\"not at all\") to 4 (\"very much\"). The total, summed score ranged from 0 to 52; lower scores indicating greater fatigue and higher score indicating better health-related quality of life. Baseline was defined as the last non-missing value prior to the first dose of subcutaneous treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":"7.178"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Treatment Administration Satisfaction Questionnaire (TASQ) Score at Day 71","description":"The Treatment Administration Satisfaction Questionnaire (TASQ) is a 19-item questionnaire that assesses treatment administration satisfaction across 5 domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each domain offers up to 5 response options; lower scores indicate a more positive response. Scoring is completed by summing each of the 5 domains. Total TASQ scores during the study ranged from 0 to 367, with a lower score indicating greater satisfaction with treatment administration.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.00","spread":"34.581"},{"groupId":"OG001","value":"-70.54","spread":"70.522"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Treatment Administration Satisfaction Questionnaire (TASQ) Score at Day 351","description":"The Treatment Administration Satisfaction Questionnaire (TASQ) is a 19-item questionnaire that assesses treatment administration satisfaction across 5 domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each domain offers up to 5 response options; lower scores indicate a more positive response. Scoring is completed by summing each of the 5 domains. Total TASQ scores during the study ranged from 0 to 367, with a lower score indicating greater satisfaction with treatment administration.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.29","spread":"80.068"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experienced Breakthrough Hemolysis up to Day 71","description":"Breakthrough hemolysis was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \\[dyspnea\\], anemia \\[hemoglobin \\<10 grams/deciliter (g/dL)\\], major adverse vascular event \\[MAVE, including thrombosis\\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2\\*upper limit of normal (ULN). Denominator for a percentage was participants with at least one post-baseline data for the period. For Through Day 71, only visits with data were used to assess breakthrough hemolysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experienced Breakthrough Hemolysis up to Day 351","description":"Breakthrough hemolysis was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \\[dyspnea\\], anemia \\[hemoglobin \\<10 g/dL\\], major adverse vascular event \\[MAVE, including thrombosis\\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2\\*ULN. Denominator for a percentage was participants with at least one post-baseline data for the period.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"3.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Transfusion Avoidance up to Day 71","description":"Transfusion Avoidance was defined as participants who remained transfusion free and did not require a transfusion after the first dose of study drug through the period of interest. Percentages are based on participants with any post-baseline data for the period. For Through Day 71, only visits with data were used to assess transfusion avoidance.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null},{"groupId":"OG001","value":"94.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Transfusion Avoidance up to Day 351","description":"Transfusion Avoidance was defined as participants who remained transfusion free and did not require a transfusion after the first dose of study drug through the period of interest. Denominator for a percentage was participants with at least one post-baseline data for the period.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":null},{"groupId":"OG001","value":"85.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained Stabilized Hemoglobin (SHg) up to Day 71","description":"SHg was defined as the avoidance of a ≥2 g/dL decrease in hemoglobin level from Baseline (defined as the last assessment prior to the first dose of the study drug) in the absence of transfusion to the end of the period of interest. Percentages were based on participants with at least one post-baseline data for the period. For Through Day 71, only visits with data were used to assess SHg.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"93.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained SHg up to Day 351","description":"SHg was defined as the avoidance of a ≥2 g/dL decrease in hemoglobin level from SC Baseline (defined as the last assessment prior to the first dose of SC treatment) in the absence of transfusion to the end of the period of interest. Denominator for a percentage was participants with at least one post-baseline data for the period. Visits were based on the number of days since first dose of SC treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7","spread":null},{"groupId":"OG001","value":"83.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":45},"commonTop":["Device delivery system issue","COVID-19","Headache","Pyrexia","Diarrhoea"]}}}